Yang H, Qiu GP, Liu J, Yang TQ. Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(11): 4392-4401 [PMID: 39554745 DOI: 10.4251/wjgo.v16.i11.4392]
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4392-4401 Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4392
Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma
Hui Yang, Guang-Ping Qiu, Jie Liu, Tie-Quan Yang
Hui Yang, Guang-Ping Qiu, Jie Liu, Tie-Quan Yang, Department of Interventional Therapy, Ningbo No. 2 Hospital, Ningbo 315000, Zhejiang Province, China
Author contributions: Yang H contributed to the conceptualization, data curation, and writing - original draft; Qiu GP and Liu J participated in the investigation of this study; Qiu GP, Liu J, and Yang TQ took part in the writing - review & editing; Qiu GP contributed to the resources of this manuscript; Liu J was involved in the investigation of this study; Yang TQ contributed to the methodology and visualization.
Institutional review board statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Ningbo No. 2 Hospital (approval No: YJ-NBEY-KY-2024-004-01; date of approval: 2024-01-16).
Informed consent statement: The need for patient consent was waived due to the retrospective nature of the study which was approved by the Ethics Committee of Ningbo No. 2 Hospital.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data underlying the findings of this study are accessible upon request to the corresponding author, owing to privacy and ethical considerations that preclude their public dissemination.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Received: June 21, 2024 Revised: September 10, 2024 Accepted: September 24, 2024 Published online: November 15, 2024 Processing time: 125 Days and 21.7 Hours
Core Tip
Core Tip: A retrospective analysis encompassing 104 patients diagnosed with large hepatocellular carcinoma (≥ 5 cm), focused on comparing the efficacy and safety of two treatment modalities, which were the triple combination therapy of drug-eluting beads transarterial chemoembolization (D-TACE), programmed cell death 1 inhibitor, and lenvatinib (D-TACE-P-L) and the triple therapy consisting of conventional TACE, programmed cell death protein 1 inhibitor, and lenvatinib. Progression-free survival, tumor response, and adverse events were compared between the two groups, and the findings revealed that D-TACE-P-L demonstrated significantly superior median progression-free survival and objective response rate, while maintaining comparable toxicity profiles. Based on these outcomes, this study proposed that the D-TACE-P-L therapy served as a preferential treatment option for individuals suffering from large hepatocellular carcinoma.
